SCHOTT Pharma Unveils Enhanced Nest Design for Polymer Syringes

SCHOTT Pharma AG & Co. KGaA, based in Mainz, Germany, has introduced an innovative nest design for prefillable polymer syringes. The new nest accommodates 160 syringes, marking a 60% increase from the standard 100-syringe capacity. This enhancement is set to boost pharma companies' operational efficiency by up to 67%, significantly reducing manufacturing costs and the product carbon footprint by 17%.

In collaboration with machine manufacturer Bausch + Ströbel, the new nest integrates seamlessly with high-tech filling lines, ensuring reliable and efficient operations. SCHOTT Pharma, a leader in drug containment solutions, leverages its 20-year expertise in the field to meet the growing demand for quick, large-scale drug production while reducing CO2 emissions.

SCHOTT Pharma's new design, part of the SCHOTT TOPPAC® Nest 160 line, aims to address the needs of drug manufacturers by enabling more efficient production of high-quality drugs, including vaccines and derma fillers, thus cutting down on total fixed costs.